SWITZERLAND’S LEADING STARTUP COMPETITION

Want to turn your innovative startup idea into reality? 

Learn how >>venture>> can you support you.

News & Events

>>venture>> Introduction to Intellectual Property - Dec. 5

This online seminar is hosted in December by the Swiss Federal Institute of Intellectual Property and...

16 Nov 2022

>>venture>> Introduction to Intellectual Property - Jan. 31

This online seminar is hosted in January by the Swiss Federal Institute of Intellectual Property and...

16 Nov 2022

Early-stage innovation got a kickstart in Western Switz...

>>venture>> kickstarted their 2023 edition at the innovation hub of Western Switzerland, EPFL.

24 Nov 2022

Why should you join >>venture>>?

Ready to turn your innovative business or NPO idea into reality? Then you’re a perfect match for >>venture>>, an annual competition that supports early-stage startups.

Awarding over half a million Swiss francs, each year we open our competition and invite you to attend our workshops, make connections in the Swiss startup scene and access our coaching and mentor network.

VENTURE_Prizes_Winner2017.jpg

Prizes

Make your startup dreams a reality with up to CHF 150,000 in cash and a business consulting package from McKinsey & Company.

VENTURE_Network

Network

Connect with mentors and get expert feedback. Make valuable contacts that will shape your future and get your business off the ground.

Venture2019_AwardCeremony_KatharinaLocher_DePoly_SamanthaAnderson2.jpg

Visibility

Make connections in the Swiss startup scene and get access to investors and top business executives in Switzerland as well as media exposure.

Shaping the companies of tomorrow

We are extremely proud of our alumni. They have accomplished great feats, and we’re confident they will continue to do so. Here are some of their stories.

Jurgi Camblong - Sophia Genetics.jpg

GLYCART

Biotech startup Glycart was a >>venture>> competition winner in 2000. Founded as a spinoff of the ETH, the company is an innovator in glycoengineering, or adding sugar chains to antibodies to make them more effective in fighting cancer and other diseases. The life-saving potential of this technology was recognized early on, prompting pharma giant Roche to acquire the startup for $235 million in 2005. A leukemia drug based on Glycart’s research received breakthrough therapy designation from the US Food and Drug Administration in 2013.

< Headquarter in Schlieren

 

Ready to venture forward?

Our Sponsors

Ascom
BCV
Basler_Kantonalbank
Leaps by Bayer
BKV
Buhler
4 Capital AG
Clariant Logo
Datwyler
Die Post
Geberit
HeiQ Logo
Hilti
Holcim Schweiz
IGE IPI
Johnson & Johnson
Julius Bär
Nagra Kudelski
Leister
LEM New Logo
die Mobiliar Logo
Molecular Partners
Nestlé Logo
Novartis
Roche
Saint-Gobain
Sensirion
Six
Skyguide Logo
Sonova Logo
Swissquote_Logo
Swiss Re
UBS
Valora
VZ New Logo
Zurich Logo New
RTS
TX Group